CoChat

The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies

Open access
Mahmoud, Ashraf Attia, Raih, Mohd Firdaus, Sage, Edison Eukun, Ali, Qurashi M., Suliman, Omnia H., Ibrahim, Sabah A. E., Mohamed, Osama, Abdelrazeg, Samar, Mohamed, Sofia B. · 2025 · PLOS One

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index; none of the 29 sources its claims cite is checked for support yet.

Abstract

The tumor suppressor protein p53 (TP53) is frequently mutated in various types of human malignancies, including HNSCC, which affects tumor growth, prognosis, and treatment. Gaining insight into the impact of TP53 mutations in HNSCC is crucial for developing new diagnostic and therapeutic methods. In this study, we aimed to investigate the influence of mutations on the structure and functions of the TP53 protein and miRNA expression using computational analysis. The genomic data of patients with HNSCC were obtained from TCGA, and the impact of mutations on the TP53 gene was investigated using different bioinformatics tools. Results: The findings showed that the TP53 mutations increased TP53 expression levels in HNSCC and were associated with a poor prognosis. Furthermore, hsa-mir-133b expression was reduced in TP53-mutated samples, significantly affecting patient survival in HNSCC. Six mutations, including R273C, G105C, G266E, Q136H/P, and R280G, were identified as deleterious, carcinogenic, driver, highly conserved, and exposed. These mutations were located in the P53 domain, and PTM analysis revealed that R280G and R273C are at a methylation site, and R273C, Q136H/P, and R280G are located in the protein pocket. The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. The molecular dynamics analysis indicates that R280G, Q136H, and G105C mutations confer a gain of function by stabilizing the TP53-substrate complex. Conclusions: Based on the research findings, the mutations on TP53 were found to have an impact on protein and miRNA expression, development, survival, and progression of HNSCC patients, and has-mir-133b could be a promising novel biomarker for monitoring the progression of HNSCC. It was discovered that G105C and Q136H/P, as novel mutations, affect the function and structure of proteins causing HNSCC, which indicates that they could be interesting subjects for further investigation, diagnostics, and therapeutic strategies. Furthermore, the precise positioning of R280G and R273C within the methylation site and Q136H/P in the binding site has been documented for the first time. Moreover, the G105C, Q136H, and R280G mutations that stabilized TP53 structure and altered its interaction dynamics with substrates may serve as novel potential diagnostic biomarkers in cancer, guiding patient stratification and personalized treatment strategies. The molecular dynamics analysis provides insights into how specific TP53 mutations impact protein structure, stability, and function upon substrate binding, highlighting their role in cancer biology and potential implications for therapeutic interventions. This paper provides a novel understanding of the mechanisms by which these mutations contribute to the development of cancer.

Overview

CoChat Summary

TL;DR

This in silico study analyzed TCGA HNSCC data and found TP53 mutations in 70% of 1,332 samples, associated with disease presence and reduced progression-free survival, with hsa-mir-133b downregulation linked to poorer survival. It prioritized six TP53 missense mutations (R273C, G105C, G266E, Q136H/P, R280G) as deleterious/driver/cancer-associated, with structural, docking, and molecular-dynamics evidence of altered DNA binding and stability.

Key findings

  • Among 319 TP53 mutations identified, missense mutations were most frequent (146), followed by 78 frameshifts, 40 splicing, 39 stop-gained, 9 inframe deletions, 6 synonymous, and 1 intron mutation; 226 substitutions, 24 insertions, and 76 deletions were found.
  • Out of 1,332 samples, 932 (70%) showed TP53 mutations. Table 1 reports altered-group survival associations: overall p=1.42E-06, disease-free p=5.28E-03, progression-free p=0.0102, and disease-specific p=0.0349; the text highlights significant association with HNSCC presence (P=0.0349) and reduced progression-free survival (P=0.0102).
  • TP53 expression was increased in TP53-mutant and nonmutant HNSCC samples versus normal tissues, but this increase had no significant survival impact (Fig 3B, P=0.12). hsa-mir-133b was significantly downregulated in both mutant and nonmutant groups and associated with poorer survival (P=0.017); hsa-mir-183 was elevated without significant survival impact (P=0.67); hsa-mir-145 was upregulated with near-significant survival correlation (P=0.056).
  • Six mutations—R273C, G105C, G266E, Q136H/P, and R280G—were identified as deleterious, carcinogenic, driver, highly conserved, and exposed, located in the P53 domain. Docking showed decreased binding affinity, with R273C, R280G, G266E, and G105C displaying the most significant differences; MD showed Apo-TP53 RMSD 26.20 Å versus wild-type 3.48 Å, and mutants G105C 3.74 Å, Q136H 4.79 Å, R280G 4.86 Å, with R280G having the lowest hydrogen-bond formation rate (0.024 ns⁻¹ vs wild-type 0.0360 ns⁻¹).

Methods

  • Data were obtained from TCGA via the Genomic Data Commons and cBioPortal, using three HNSCC studies: TCGA Firehose Legacy (530 samples), TCGA Nature 2015 (279 samples), and TCGA Pan Cancer Atlas (523 samples). UALCAN was used to assess TP53 and miRNA-seq expression (hsa-mir-183, hsa-mir-133b, hsa-mir-145) in relation to TP53 mutations.
  • Mutation impact was assessed with multiple in silico tools: VEP, SIFT, Polyphen, PhD-SNP, PANTHER, SNPs&GO, CScape, CScape-somatic, FATHMM, I-Mutant2.0, CUPSAT, MUpro, ConSurf, Mutation3D, GPS 5.0/GPS-MSP, CASTp, SOPMA, HOPE, and UCSF Chimera. PPI networks were built with STRING and visualized in Cytoscape.
  • Structural analyses included docking with AutoDock, HDock, and pyDOCK using PDB 2AC0, and molecular dynamics simulations with NAMD/VMD using TIP3P solvation, 200 ns simulations, 100,000,000 steps, 310 K, NVE ensemble, and PME for long-range electrostatics.

Limitations

  • Stated in the paper: the study is based entirely on in silico analyses, and no experimental validation was conducted to confirm the computational predictions.
  • Stated in the paper: the dataset primarily uses publicly available TCGA data, which may not represent all demographic and geographic populations affected by HNSCC.
  • Evident from the text: the findings rely on multiple computational prediction tools and public datasets, and the authors call for experimental validation, development of therapies targeting key TP53 mutations, integration of mutation profiling into clinical practice, and expanded analysis across diverse populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0307859

Cites

31 of 32 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 (A) Pie chart showing the distribution of mutation types identified within the TP53 gene. The chart highlights the predominance of missense mutations, followed by frameshift and splice-site mutations, with each category represented as a proportion of the total observed mutations. (B) Bar graph presenting the frequency of different splice mutation types in the TP53 gene, categorized into donor site mutations, acceptor site mutations, and mutations within the splice region.
Fig 1 (A) Pie chart showing the distribution of mutation types identified within the TP53 gene. The chart highlights the predominance of missense mutations, followed by frameshift and splice-site mutations, with each category represented as a proportion of the total observed mutations. (B) Bar graph presenting the frequency of different splice mutation types in the TP53 gene, categorized into donor site mutations, acceptor site mutations, and mutations within the splice region.CC BY · PubMed Central
Fig 2 Graph illustrating the distribution of mutations across 20 genes. Each bar represents a specific gene, and the height of the bar corresponds to the frequency of mutations identified within that gene. This visualization highlights the variability in mutation density among the analyzed genes, with some genes showing a higher mutation frequency than others.
Fig 2 Graph illustrating the distribution of mutations across 20 genes. Each bar represents a specific gene, and the height of the bar corresponds to the frequency of mutations identified within that gene. This visualization highlights the variability in mutation density among the analyzed genes, with some genes showing a higher mutation frequency than others.CC BY · PubMed Central
Fig 3 (A) TP53 expression levels are elevated in TP53-mutant and nonmutant HNSC samples compared to normal tissues. (B) Kaplan-Meier analysis shows a trend of improved survival in HNSC patients with high TP53 expression, though not statistically significant (P = 0.12). (C) TP53 expression is high across several cancer types, with variation observed between tumor types.
Fig 3 (A) TP53 expression levels are elevated in TP53-mutant and nonmutant HNSC samples compared to normal tissues. (B) Kaplan-Meier analysis shows a trend of improved survival in HNSC patients with high TP53 expression, though not statistically significant (P = 0.12). (C) TP53 expression is high across several cancer types, with variation observed between tumor types.CC BY · PubMed Central
Fig 4 (A) The distribution of mutations within the 3D structure of the TP53 protein. (B) Structural alteration of the wild type residue G266E by Project Hope. The wild type residue is presented as yellow and the mutant residue is shown in red. (C) The illustration represented mutations occurring in the P53 domain of the TP53 protein.
Fig 4 (A) The distribution of mutations within the 3D structure of the TP53 protein. (B) Structural alteration of the wild type residue G266E by Project Hope. The wild type residue is presented as yellow and the mutant residue is shown in red. (C) The illustration represented mutations occurring in the P53 domain of the TP53 protein.CC BY · PubMed Central
Fig 5 Structural alterations in hydrogen bond networks of the TP53 protein caused by mutations G266E (A-B), G105C (C-D), R273C (E-F), R280G (G-H), and Q136P (I-J). Wild-type structures (left panels) and mutant structures (right panels) highlight the disruption of key hydrogen bonds (blue dashed lines) and changes in residue interactions (green sticks). Mutated residues are marked in red, demonstrating destabilizing effects on the TP53 conformation and DNA-binding ability. Yellow ribbons represent the protein backbone, emphasizing structural distortions caused by each mutation.
Fig 5 Structural alterations in hydrogen bond networks of the TP53 protein caused by mutations G266E (A-B), G105C (C-D), R273C (E-F), R280G (G-H), and Q136P (I-J). Wild-type structures (left panels) and mutant structures (right panels) highlight the disruption of key hydrogen bonds (blue dashed lines) and changes in residue interactions (green sticks). Mutated residues are marked in red, demonstrating destabilizing effects on the TP53 conformation and DNA-binding ability. Yellow ribbons represent the protein backbone, emphasizing structural distortions caused by each mutation.CC BY · PubMed Central
Fig 6 Structural clashes in TP53 mutants: (A) G266E mutation causes steric clashes with PHE109 and LEU257, destabilizing the structure. (B) G105C mutation disrupts interactions with residues LEU265, TYR103, TYR107, and GLN104. (C) Q136H mutation alters interactions with nearby residues (ALA119, THR123, LEU137, LYS139, ASP281, ARG273, ARG282), affecting protein stability.
Fig 6 Structural clashes in TP53 mutants: (A) G266E mutation causes steric clashes with PHE109 and LEU257, destabilizing the structure. (B) G105C mutation disrupts interactions with residues LEU265, TYR103, TYR107, and GLN104. (C) Q136H mutation alters interactions with nearby residues (ALA119, THR123, LEU137, LYS139, ASP281, ARG273, ARG282), affecting protein stability.CC BY · PubMed Central
Fig 7 Redocking results showing the interaction between the TP53 protein (white ribbon) and its DNA dodecamer ligand (magenta and blue) from PDB ID: 2AC0, highlighting the binding conformation.
Fig 7 Redocking results showing the interaction between the TP53 protein (white ribbon) and its DNA dodecamer ligand (magenta and blue) from PDB ID: 2AC0, highlighting the binding conformation.CC BY · PubMed Central
Fig 8 Molecular dynamics simulation results for Apo-TP53 (red), wild-typeTP53. DNAcomplex(purple), and the complexes between DNA substrate and TP53 mutants; G105C(green), Q136H (yellow), R280G (blue).(A) Root Mean Square Deviation (RMSD) analysis, (B) RootMeanSquare Fluctuation(RMSF) analysis, (C) Hydrogen bonding analysis, (D) Solvent accessible surface area analysis, and (E) Radius of gyration on analysis.
Fig 8 Molecular dynamics simulation results for Apo-TP53 (red), wild-typeTP53. DNAcomplex(purple), and the complexes between DNA substrate and TP53 mutants; G105C(green), Q136H (yellow), R280G (blue).(A) Root Mean Square Deviation (RMSD) analysis, (B) RootMeanSquare Fluctuation(RMSF) analysis, (C) Hydrogen bonding analysis, (D) Solvent accessible surface area analysis, and (E) Radius of gyration on analysis.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 29 Not checked · 139 Own results and interpretations

102 more claims

Create a free account to see all 169 claims and to verify the 29 references still open.

See all claims — free account
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 32 references

Research works printed but not linked: 4

  1. Zhang Y, Dai Y, Liu S, et al. Exome and whole-genome sequencing identified frequent and unique mutations in head and neck squamous cell carcinoma. Front Genet. 2021; 12: 721315. doi: 10.3389/fgene.2021.721315 · doi:10.3389/fgene.2021.721315
  2. The Cancer Genome Atlas Research Network. The Cancer Genome Atlas (TCGA): exploring the DNA of cancer. Nat Rev Cancer. 2013; 13(10): 714– 26. doi: 10.1038/nrc3587 24060863 · DOI
  3. Smith JA. Docking analysis using AutoDock and HDock Server. J Comput Chem. 2020; 25(4): 123– 45. doi: 10.1234/jcc.2020.5678 · doi:10.1234/jcc.2020.5678
  4. Smith J, Doe A. Analysis of TP53-related genes and their interactions. J Mol Biol. 2023; 120(3): 456- 467. doi: 10.1016/j.jmb.2023.01.012 · doi:10.1016/j.jmb.2023.01.012

Cited by

Metadata

Authors
Mahmoud, A. A., Raih, M. F., Sage, E. E., Ali, Q. M., Suliman, O. H., Ibrahim, S. A. E., Mohamed, O., Abdelrazeg, S., & Mohamed, S. B.
Affiliations
  • National University (SD)
  • National University of Malaysia (MY)
Corresponding author
Mohamed, Sofia B.
Venue
PLOS One
Published
2025-05-07
Volume
20
Issue
5
Pages
e0307859
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4410153493
Cited by
4
References
31
Citations by year
2026: 3 · 2025: 1
FWCI
1.32
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Open Access Institutional Repository at Robert Gordon University (Robert Gordon University) (publishedVersion, other-oa)
  • Open Access Institutional Repository at Robert Gordon University (Robert Gordon University) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Universiti Kebangsaan Malaysia ((DIP-2023-XX))
  • National University-Sudan (NUSU, 2022,007)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
TP53 mutation, head and neck squamous cell carcinoma, microRNA expression, protein-DNA binding affinity, gain-of-function mutations, prognostic factors
MeSH terms
Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Humans, Mutation, Prognosis, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.